Decision Resources, Inc., Dec 2009, Pages: 27
—that is, whether or not to allow U.S. citizens to purchase prescriptiondrugs from Canada. While factors such as the U.S. Medicare Drug Benefit for seniors, a rising Canadian dollar, manufacturers’ limits
Decision Resources, Inc., March 2009, Pages: 35
Expenditures, 1996-2007
- U.S. Residents’ Source of PrescriptionDrug Benefi ts, July 2008
- Growth Rate of Overall U.S. Healthcare Expenditures and PrescriptionDrug Spending in Select Years, 1970
Decision Resources, Inc., July 2010, Pages: 40
in Japan are generally marginally higher than European prices but lower than U.S. prices. How do drug prices in Japan compare overall with pharmaceutical prices in the United States? To what extent do
Decision Resources, Inc., Aug 2008, Pages: 47
of the Medicare Population 23
Regulatory Reforms 24
Changing Political Climate 25
Senator Barack Obama 25
Senator John McCain 26
List of Tables
1. Select Brand-Name Cardiovascular Drugs with 2007 U.S. Sales 7
2
Decision Resources, Inc., May 2007, Pages: 23
:
- In January 2007, U.S. lawmakers proposed a series of bills to improve U.S. consumers’ access to low priced generic drugs, including bio generics. Which bills have been proposed, how much savings
Decision Resources, Inc., May 2011
of the prescriptiondrug market set to continue; delay to U.K. healthcare reform legislation; introduction of value-based pricing in the United Kingdom; local restrictions on the reimbursement of certain drugs
Decision Resources, Inc., May 2009, Pages: 40
the elderly.
- What are these therapeutic indications? How much money do U.S. residents spend on these indications?
- The seven major markets differ in their prescriptiondrug coverage. How do these countries
Frost & Sullivan, March 2008
Market among Ambulatory Care Providers: Forecasts of the Number of Prescriptions Written (U.S.), 2003-2013
- Total e-Prescribing Market among Ambulatory Care Providers: Forecasts of the Number of Prescriptions
Decision Resources, Inc., June 2007, Pages: 35
PrescriptionDrug Spending Growth, 1988-2016
2. United States Expenditures on PrescriptionDrugs, 2000, 2005, and 2016
3. PrescriptionDrug State Legislation, 2007
4. Drug Reimportation Timeline: Politics
Mintel, Jan 2011, Pages: 127
and diet
Herbal supplements and nontraditional medications
Over-the-counter remedies
Prescription remedies
Health insurance
Marketing strategies
U.S. Black and Hispanic population
Insights and Opportunities
Decision Resources, Inc., Sep 2006, Pages: 30
?
Scope
Retiree benefits: overview of Medicare drug benefit program; the impact of increasing coinsurance for seniors in Japan; U.S. employers’ plan to restrict retirees’ health benefits.
Growth of generics
Decision Resources, Inc., Jan 2009, Pages: 36
is the economic downturn affecting U.S. residents’ use of prescriptiondrugs and healthcare services? What reforms do the Democrats plan to implement to improve access to affordable healthcare and medications? What
Decision Resources, Inc., June 2007, Pages: 33
2007
4. U.S. Employers’ Views on Strategies to Increase PrescriptionDrug Benefit Value
5. U.S. Employers’ Views on Strategies to Increase PrescriptionDrug Benefit Value
Figures:
1. New Drugs’ Share
Decision Resources, Inc., Feb 2008, Pages: 74
will this enormous growth in Medicare’s share of total U.S. drugexpenditures affect private insurers? Will it encourage employers to reduce or eliminate retiree benefits? How might the 2008 Medicare drug benefit
Nutrition Business Journal, March 2011
, 2003-2010e
Figure 4 2 U.S. Gross Domestic Product vs. National Healthcare Expenditures Growth, 2000-2010e
Figure 4 3 U.S. PrescriptionDrug, OTC and Supplement Product Sales Growth, 2000-2010e
Figure
Decision Resources, Inc., June 2009, Pages: 31
European markets. How do Chinese prices compare with prices in the United States? Which kinds of drugs have prices close to, or higher than, U.S. prices?
- Hospitals are the dominant distribution channel
Fuji-Keizai USA, Inc., June 2009, Pages: 126
Drug Market Forecast 2008 – 2013 by Product in $Million
2.1.1.2 Market Restraints
Table 2-2. U.S. Patent Expirations of Leading Prescription Allergy Drugs
2.1.2 Rx Allergy Drug Market Forecast by Region
Fuji-Keizai USA, Inc., June 2009, Pages: 126
Market Forecast 2008 – 2013 by Product in $Million
2.1.1.2 Market Restraints
Table 2-2. U.S. Patent Expirations of Leading Prescription Allergy Drugs
2.1.2 Rx Allergy Drug Market Forecast by Region
Table 2-3. Rx
